Brepocitinib improves skin disease outcomes in dermatomyositis trial

This prespecified secondary analysis of the phase 3 VALOR trial evaluated brepocitinib, an oral TYK2/JAK1 inhibitor, on cutaneous outcomes in 241 adults with dermatomyositis over 52 weeks. The trial reported that brepocitinib 30 mg outperformed placebo on skin disease activity (CDASI-A), itch remission, skin-related quality of life, and rates of clear/almost clear skin and functional skin remission, with benefits observed from week 4 through week 52 and a safety profile the authors describe as consistent with approved JAK and TYK2 inhibitors.

Most relevant for: Adults with dermatomyositis who have active cutaneous disease, including those with moderate to severe skin involvement.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.